Isoflavone(Phytogen) in the Treatment of Male Climacterics and Prostatism

Ming Che Liu, Han-Sun Chiang, Kuan-Chou Chen, K.J. Hsieh

Research output: Contribution to journalArticle

10 Downloads (Pure)

Abstract

Background and purpose: To elucidate the effect of isoflavone on male climacterics and
prostatism. Methods: We conducted an open labeled clinical study of isoflavone on 25
males with climacteric symptoms and/or prostatism, in which 6 g of isoflavone (Phytogen)
was given daily to 25 men aged from 48 to 78 (average, 67.2) years old for 2 months.
Periodic examinations were made of the prostate size, PSA (prostate specific antigen), and
uroflow, as well as a follow up questionnaires with subjective screening of the voiding
function, sexual function, and male climacteric symptoms were given. Results: Neither the
prostate size nor serum PSA level of any patient were altered. For patients with
hypogonadism at the baseline (with an average serum testosterone level of 0.74 ng/ml,
n=8), isoflavone was shown to have resolved the testosterone deficiency after 1 month
(average testosterone level of 3.04 ng/ml) and 2 months (average testosterone level of 3.37
ng/ml) of treatment. The peak flow rate of the urine was also notably improved after 2
months of isoflavone treatment (with an increase in the average peak flow rate of from
6.17 to 12 ml/s). Some of the male climacteric symptoms such as fatigue, general
weakness, and skin atrophy were found to have diminished by scoring in the group of
diseased patients. As a natural product, isoflavone was quite acceptable to these middle
aged to elderly patients, and no adverse effects were recorded. Conclusion: Although
neither all of the patients nor all of the symptoms were responsive to 2 months of treatment
with this medication in our series, isoflavone did, however, truly benefit some patients with
climacteric symptoms and/or prostatism and may be an alternative therapy for aging males.
Original languageEnglish
Pages (from-to)249-256
Number of pages8
JournalFu-Jen Journal of Medicine
Publication statusPublished - 2004

Fingerprint

Prostatism
Isoflavones
Testosterone
Prostate-Specific Antigen
Therapeutics
Complementary Therapies
Biological Products
Serum
Atrophy
Fatigue
Prostate
Urine
Skin

Keywords

  • isoflavone
  • climacterics symptoms
  • prostatism
  • aging male

Cite this

Isoflavone(Phytogen) in the Treatment of Male Climacterics and Prostatism. / Liu, Ming Che; Chiang, Han-Sun; Chen, Kuan-Chou; Hsieh, K.J.

In: Fu-Jen Journal of Medicine, 2004, p. 249-256.

Research output: Contribution to journalArticle

@article{ee0401039c2d4852bb67669c86fa3c4d,
title = "Isoflavone(Phytogen) in the Treatment of Male Climacterics and Prostatism",
abstract = "Background and purpose: To elucidate the effect of isoflavone on male climacterics andprostatism. Methods: We conducted an open labeled clinical study of isoflavone on 25males with climacteric symptoms and/or prostatism, in which 6 g of isoflavone (Phytogen)was given daily to 25 men aged from 48 to 78 (average, 67.2) years old for 2 months.Periodic examinations were made of the prostate size, PSA (prostate specific antigen), anduroflow, as well as a follow up questionnaires with subjective screening of the voidingfunction, sexual function, and male climacteric symptoms were given. Results: Neither theprostate size nor serum PSA level of any patient were altered. For patients withhypogonadism at the baseline (with an average serum testosterone level of 0.74 ng/ml,n=8), isoflavone was shown to have resolved the testosterone deficiency after 1 month(average testosterone level of 3.04 ng/ml) and 2 months (average testosterone level of 3.37ng/ml) of treatment. The peak flow rate of the urine was also notably improved after 2months of isoflavone treatment (with an increase in the average peak flow rate of from 6.17 to 12 ml/s). Some of the male climacteric symptoms such as fatigue, generalweakness, and skin atrophy were found to have diminished by scoring in the group ofdiseased patients. As a natural product, isoflavone was quite acceptable to these middleaged to elderly patients, and no adverse effects were recorded. Conclusion: Althoughneither all of the patients nor all of the symptoms were responsive to 2 months of treatmentwith this medication in our series, isoflavone did, however, truly benefit some patients withclimacteric symptoms and/or prostatism and may be an alternative therapy for aging males.",
keywords = "isoflavone, climacterics symptoms, prostatism, aging male, 男性更年期, 攝護腺肥大症狀 , 男性老化",
author = "Liu, {Ming Che} and Han-Sun Chiang and Kuan-Chou Chen and K.J. Hsieh",
year = "2004",
language = "English",
pages = "249--256",
journal = "Fu-Jen Journal of Medicine",

}

TY - JOUR

T1 - Isoflavone(Phytogen) in the Treatment of Male Climacterics and Prostatism

AU - Liu, Ming Che

AU - Chiang, Han-Sun

AU - Chen, Kuan-Chou

AU - Hsieh, K.J.

PY - 2004

Y1 - 2004

N2 - Background and purpose: To elucidate the effect of isoflavone on male climacterics andprostatism. Methods: We conducted an open labeled clinical study of isoflavone on 25males with climacteric symptoms and/or prostatism, in which 6 g of isoflavone (Phytogen)was given daily to 25 men aged from 48 to 78 (average, 67.2) years old for 2 months.Periodic examinations were made of the prostate size, PSA (prostate specific antigen), anduroflow, as well as a follow up questionnaires with subjective screening of the voidingfunction, sexual function, and male climacteric symptoms were given. Results: Neither theprostate size nor serum PSA level of any patient were altered. For patients withhypogonadism at the baseline (with an average serum testosterone level of 0.74 ng/ml,n=8), isoflavone was shown to have resolved the testosterone deficiency after 1 month(average testosterone level of 3.04 ng/ml) and 2 months (average testosterone level of 3.37ng/ml) of treatment. The peak flow rate of the urine was also notably improved after 2months of isoflavone treatment (with an increase in the average peak flow rate of from 6.17 to 12 ml/s). Some of the male climacteric symptoms such as fatigue, generalweakness, and skin atrophy were found to have diminished by scoring in the group ofdiseased patients. As a natural product, isoflavone was quite acceptable to these middleaged to elderly patients, and no adverse effects were recorded. Conclusion: Althoughneither all of the patients nor all of the symptoms were responsive to 2 months of treatmentwith this medication in our series, isoflavone did, however, truly benefit some patients withclimacteric symptoms and/or prostatism and may be an alternative therapy for aging males.

AB - Background and purpose: To elucidate the effect of isoflavone on male climacterics andprostatism. Methods: We conducted an open labeled clinical study of isoflavone on 25males with climacteric symptoms and/or prostatism, in which 6 g of isoflavone (Phytogen)was given daily to 25 men aged from 48 to 78 (average, 67.2) years old for 2 months.Periodic examinations were made of the prostate size, PSA (prostate specific antigen), anduroflow, as well as a follow up questionnaires with subjective screening of the voidingfunction, sexual function, and male climacteric symptoms were given. Results: Neither theprostate size nor serum PSA level of any patient were altered. For patients withhypogonadism at the baseline (with an average serum testosterone level of 0.74 ng/ml,n=8), isoflavone was shown to have resolved the testosterone deficiency after 1 month(average testosterone level of 3.04 ng/ml) and 2 months (average testosterone level of 3.37ng/ml) of treatment. The peak flow rate of the urine was also notably improved after 2months of isoflavone treatment (with an increase in the average peak flow rate of from 6.17 to 12 ml/s). Some of the male climacteric symptoms such as fatigue, generalweakness, and skin atrophy were found to have diminished by scoring in the group ofdiseased patients. As a natural product, isoflavone was quite acceptable to these middleaged to elderly patients, and no adverse effects were recorded. Conclusion: Althoughneither all of the patients nor all of the symptoms were responsive to 2 months of treatmentwith this medication in our series, isoflavone did, however, truly benefit some patients withclimacteric symptoms and/or prostatism and may be an alternative therapy for aging males.

KW - isoflavone

KW - climacterics symptoms

KW - prostatism

KW - aging male

KW - 男性更年期

KW - 攝護腺肥大症狀

KW - 男性老化

M3 - Article

SP - 249

EP - 256

JO - Fu-Jen Journal of Medicine

JF - Fu-Jen Journal of Medicine

ER -